Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2022-06-02 00:00:00 ET · period of report 2022-05-31 · accession 0001209191-22-033485 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-02 | 2022-05-31 | VERA | Curley Joanne | Chief Development Off | S - Sale+OE | $15.22 | -400 | 25.2K | -2% | -$6,088 |
| D | 2022-06-02 | 2022-05-31 | VERA | Curley Joanne | Chief Development Off | M - OptEx | $6.37 | +400 | 25.6K | +2% | +$2,548 |
| D | 2022-06-02 | 2022-05-31 | VERA | Curley Joanne | Chief Development Off | M - OptEx | $0.00 | -400 | 25.5K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-05-31 | S | D | 400 | $15.22 | 25,194 | D | — | — | (F3) The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.10 to $15.53, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Class A Common Stock | 2022-05-31 | M | A | 400 | $6.37 | 25,594 | D | — | — | (F1) Includes 1,461 shares acquired under the Issuer's Employee Stock Purchase Plan on March 11, 2022. |
| 3 | Derivative | Stock Option (right to buy) | 2022-05-31 | M | D | 400 | $0.00 | 25,491 | D | $6.37 · — to 2030-03-31 | 400 Class A Common Stock | (F4) 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. |